This invention discloses 2.alpha.-methyl and 2.beta.-methyl analogs of 19,26,27-trinor-(20S)-1.alpha.-hydroxyvitamin D.sub.3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. These compounds may also be used for the treatment or prevention of obesity.

 
Web www.patentalert.com

> 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses

~ 00361